Cargando…

SGLT2i versus ARNI in heart failure with reduced ejection fraction: a systematic review and meta‐analysis

AIMS: This study aimed to determine the effects of sodium‐glucose cotransporter‐2 inhibitor (SGLT2i) in heart failure with reduced ejection fraction (HFrEF), compare the effect of SGLT2i with angiotensin receptor neprilysin inhibitor (ARNI), and find whether combination of SGLT2i and ARNI is better...

Descripción completa

Detalles Bibliográficos
Autores principales:	Yan, Yuling, Liu, Bin, Du, Jun, Wang, Jing, Jing, Xiaodong, Liu, Yajie, Deng, Songbai, Du, Jianlin, She, Qiang
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2021
Materias:	Original Research Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8120387/ https://www.ncbi.nlm.nih.gov/pubmed/33749159 http://dx.doi.org/10.1002/ehf2.13313

Ejemplares similares

Combined effects of ARNI and SGLT2 inhibitors in diabetic patients with heart failure with reduced ejection fraction
por: Kim, Hyue Mee, et al.
Publicado: (2021)

Will introduction of ARNI reduce the need of device therapy in heart failure with reduced ejection fraction?
por: Kaur, Navjyot, et al.
Publicado: (2021)

SGLT2 inhibitors in heart failure with reduced ejection fraction
por: Das, Uday Sankar, et al.
Publicado: (2021)

Global Benefit of SGLT2 Inhibitors in Heart Failure With Reduced Ejection Fraction
por: Brownell, Nicholas K., et al.
Publicado: (2022)

Retrospective analysis of SGLT2 inhibitors in heart failure with preserved ejection fraction
por: Clemmer, John S., et al.
Publicado: (2023)

Emerging therapies: The potential roles SGLT2 inhibitors, GLP1 agonists, and ARNI therapy for ARNI pulmonary hypertension
por: King, Nicholas E., et al.
Publicado: (2022)

Real-world comparative effectiveness of ARNI versus ACEi/ARB in HF with reduced or mildly reduced ejection fraction
por: Fu, Michael, et al.
Publicado: (2022)

Bone morphogenetic protein 4 promotes the differentiation of Tbx18-positive epicardial progenitor cells to pacemaker-like cells
por: Wu, Ling, et al.
Publicado: (2019)

ARNI and SGLT2i: a promising association to be used with caution
por: Herbst, Andrea, et al.
Publicado: (2020)

Response to cardiac resynchronization therapy and treatment with ARNi and iSGLT2
por: Fonderico, C, et al.
Publicado: (2023)

Emerging Horizons in Heart Failure with Preserved Ejection Fraction: The Role of SGLT2 Inhibitors
por: Heath, Rebecca, et al.
Publicado: (2022)

Potential Mechanisms of SGLT2 Inhibitors for the Treatment of Heart Failure With Preserved Ejection Fraction
por: Pabel, Steffen, et al.
Publicado: (2021)

Angiotensin Receptor-Neprilysin Inhibition (ARNI) in Heart Failure
por: Greenberg, Barry
Publicado: (2020)

Use of SGLT2i and ARNi in patients with atrial fibrillation and heart failure in 2021–2022: an analysis of real-world data
por: Alonso, Alvaro, et al.
Publicado: (2023)

Hypoxia induced the differentiation of Tbx18-positive epicardial cells to CoSMCs
por: Jing, Xiaodong, et al.
Publicado: (2016)

SGLT2i‑treated heart failure patients with a reduced ejection fraction: A meta‑analysis
por: Ye, Qiang, et al.
Publicado: (2023)

Emerging concepts in heart failure management and treatment: focus on SGLT2 inhibitors in heart failure with preserved ejection fraction
por: De Lorenzi, Andrea Beatriz, et al.
Publicado: (2023)

The dawn of the four-drug era? SGLT2 inhibition in heart failure with reduced ejection fraction
por: Genuardi, Michael V., et al.
Publicado: (2021)

EMPEROR-Preserved: SGLT2 inhibitors breakthrough in the management of heart failure with preserved ejection fraction
por: Wagdy, Kerolos, et al.
Publicado: (2021)

The effects of lipid-lowering therapy on coronary plaque regression: a systematic review and meta-analysis
por: Li, Yingrui, et al.
Publicado: (2021)

A clinical experience of Indian patients with heart failure with reduced left ventricular ejection fraction using an angiotensin receptor-neprilysin inhibitor [ARNI] on an outpatient basis
por: Jariwala, Pankaj, et al.
Publicado: (2021)

Sacubitril/valsartan reduces indications for arrhythmic primary prevention in heart failure with reduced ejection fraction: insights from DISCOVER-ARNI, a multicenter Italian register
por: Pastore, Maria Concetta, et al.
Publicado: (2021)

The SGLT2 inhibitor dapagliflozin in heart failure with preserved ejection fraction: a multicenter randomized trial
por: Nassif, Michael E., et al.
Publicado: (2021)

Trends of ARNI and Other Heart Failure Medication Use in Older Adults
por: Lee, Yu-Chien, et al.
Publicado: (2021)

Left atrial ejection fraction and outcomes in heart failure with preserved ejection fraction
por: Kanagala, Prathap, et al.
Publicado: (2019)

Risk Related to Pre–Diabetes Mellitus and Diabetes Mellitus in Heart Failure With Reduced Ejection Fraction: Insights From Prospective Comparison of ARNI With ACEI to Determine Impact on Global Mortality and Morbidity in Heart Failure Trial
por: Kristensen, Søren L., et al.
Publicado: (2016)

Antibodies Can Last for More Than 1 Year After SARS-CoV-2 Infection: A Follow-Up Study From Survivors of COVID-19
por: Xiao, Kaihu, et al.
Publicado: (2021)

364 Beneficial Actions of SGLT2 Inhibition and H2S Therapy in Heart Failure with Preserved Ejection Fraction
por: Doiron, Jake, et al.
Publicado: (2023)

SGLT2 inhibitors for patients with heart failure with preserved ejection fraction in China: a cost-effectiveness study
por: Lu, He, et al.
Publicado: (2023)

Impact of SGLT2 Inhibitor Therapy on Right Ventricular Function in Patients with Heart Failure and Reduced Ejection Fraction
por: Mustapic, Ivona, et al.
Publicado: (2022)

ARNI versus ACEI/ARB in Reducing Cardiovascular Outcomes after Myocardial Infarction
por: She, Jianqing, et al.
Publicado: (2021)

Determinants of ejection fraction improvement in heart failure patients with reduced ejection fraction
por: Liu, Dan, et al.
Publicado: (2023)

Efficacy and safety of spironolactone in the heart failure with mid-range ejection fraction and heart failure with preserved ejection fraction: A meta-analysis of randomized clinical trials
por: Xiang, Yajie, et al.
Publicado: (2019)

Genetic architecture of heart failure with preserved versus reduced ejection fraction
por: Joseph, Jacob, et al.
Publicado: (2022)

Cost-Effectiveness of Adding SGLT2 Inhibitors to Standard Treatment for Heart Failure With Reduced Ejection Fraction Patients in China
por: Jiang, Yaohui, et al.
Publicado: (2021)

Clinical Considerations for Use of SGLT2 Inhibitor Therapy in Patients with Heart Failure and Reduced Ejection Fraction: A Review
por: Jhalani, Nisha B.
Publicado: (2022)

Heart Failure With Midrange Ejection Fraction: Prior Left Ventricular Ejection Fraction and Prognosis
por: Zhang, Xinxin, et al.
Publicado: (2021)

Heart failure with preserved ejection fraction
por: Rigolli, Marzia, et al.
Publicado: (2013)

Heart failure with preserved ejection fraction
por: ElGuindy, Ahmed, et al.
Publicado: (2012)

Prognostic Value of Anxiety Between Heart Failure With Reduced Ejection Fraction and Heart Failure With Preserved Ejection Fraction
por: Lin, Tin‐Kwang, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_8fk6c6trphjgprsu73qdc2jijr